louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05980325: Exercise for Fighting Oncology Repercussions After Treatment
Official title: Exercise for Fighting Oncology Repercussions After Treatment: the EFFORT Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Neoplasms
Keywords: Neoplasms
Exercise Therapy
Side Effects
Cancer-related Fatigue
Quality of Life
Lead sponsor: Universitat Pompeu Fabra
Sponsor class: OTHER
Collaborators: name: Col·legi de Fisioterapeutes de Catalunya
name: Ajuntament de Mataró
First posted: 2023-08-08
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Cancer survival rates are currently on the verge of 70% at 5 years since diagnosis. Recent improvements in main cancer therapies including chemotherapy, radiotherapy, surgery and immunotherapy as well as developments of new biological therapies have significantly improved survival rates but unfortunately, cancer-related side effects continue to affect many patients even years after completion of main treatments. Exercise has been shown to not only ameliorate cancer-related effects before, during and after treatment but also improve disease-free and overall survival rates by decreasing risk factors associated with cancer risk and improving resilience to treatment. In this non-randomised, three-arm study, we aim to assess the effects of three forms of exercise (i.e: Nordic Walking, Aquatic Exercise and Functional Exercise) on physical performance, cancer-related fatigue, health-related quality of life and cancer-specific symptoms in a wide range of cancer survivors.


Eligibility criteria: Inclusion Criteria:

* Adults diagnosed with cancer
* Completion of any cancer therapy in the previous 3 months with the exception of hormonal therapy
* Patients living within the Maresme Area
* No contraindications for exercise (oncology clearance or Physical Activity Readiness Questionnaire negative)

Exclusion Criteria:

* Patients with any neurologic, cognitive or musculoskeletal impairments that prevent them to engage in any assessment test or exercise modality.
* Patients with unstable cardiac, respiratory or metabolic diseases
* Unable to speak or read Catalan or Spanish

Primary outcomes:
measure: Health-Related Quality of Life
timeFrame: 12 weeks from baseline
Secondary outcomes:
measure: Cancer-related fatigue
timeFrame: 12 weeks from baseline
measure: Cardiorespiratory fitness
timeFrame: 12 weeks from baseline
measure: Estimated one-repetition maximum
timeFrame: 12 weeks from baseline
measure: Lower limb muscle endurance
timeFrame: 12 weeks from baseline
measure: Functional capacity
timeFrame: 12 weeks from baseline
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06483425: A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer
Official title: A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Ovarian Cancer
Biomarker
Lead sponsor: Tongji Hospital
Sponsor class: OTHER
First posted: 2024-07-03
Enrollment: 2000
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with Ovarian cancer, who are willing to participate in this study and agree to donate samples for sequencing could be included.

Brief summary: This clinical trial aims to investigate the role of biomarkers in guiding precision treatment for ovarian cancer. The study will explore the effectiveness of personalized treatment strategies based on specific biomarkers identified in ovarian cancer patients. By analyzing the correlation between biomarker profiles and treatment outcomes, the trial seeks to optimize treatment decisions and improve overall survival rates in ovarian cancer patients.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with ovarian cancer.
* Willingness to undergo biomarker testing.
* Ability to provide informed consent for participation in the study.

Exclusion Criteria:

* Inability to comply with study requirements or follow-up visits.
* Previous participation in a conflicting clinical trial.

Primary outcomes:
measure: Biomarker explorarion
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
state: Hubei
Study officials:
References:
Clinical trial NCT02801825: Ultrasound-guided Axillary Artery vs Femoral Artery Cannulation.
Official title: A Randomized Study of Ultrasound-guided Axillary and Femoral Artery Cannulation in Mechanically Ventilated Critically Ill Patients.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Critical Illness
Keywords: axillay artery
cannulation
femoral artery
Lead sponsor: Uniwersytecki Szpital Kliniczny w Opolu
Sponsor class: OTHER
First posted: 2016-06-16
Enrollment: 110
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main purpose of the study is to compare two ultrasound-guided arterial cannulation procedures: in-plane infraclavicular axillary artery cannulation and out-of-plane femoral artery cannulation.


Eligibility criteria: Inclusion Criteria:

mechanically ventilated critically ill patients with indications for artery cannulation:

* in whom radial artery cannulation is unable to perform or
* in order to conduct hemodynamic monitoring using transpulmonary thermodilution

Exclusion Criteria:

* age less than 18 years
* trauma and hematoma at the catheterization site
* clinically significant coagulation disorders
* infection at the catheterization site
* lack of patients or closest relatives contents
* precedent surgery operation into the femoral and axillary arteries
* clinically significant ischemia of the limb at the cannulation side

Primary outcomes:
measure: Cannulation success rate
timeFrame: 24 hours
Secondary outcomes:
measure: Procedure complication rate.
timeFrame: 24 hours
measure: Number of puncture attempts.
timeFrame: 24 hours
Other outcomes:
Locations:
city: Opole
country: Poland
facility: Department of Anesthesiology and Intensive Care, Uniwersytecki Szpital Kliniczny w Opolu
Study officials:
affiliation: Department of Anesthesiology and Intensive Care, Uniwersytecki Szpital Kliniczny w Opolu
name: Ryszard Gawda, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00174525: Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's Disease
Official title: A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Alzheimer's Disease
Keywords: Alzheimer's Caregivers
Alzheimer disease
Lead sponsor: Pharmacology Research Institute
Sponsor class: OTHER
First posted: 2005-09-15
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This research study will assess whether AAB-001 is safe, well tolerated and effective for use in patients with Alzheimer's Disease. AAB-001 is a new drug that is not available outside this study. AAB-001 is an antibody (a type of protein usually produced by white blood cells to destroy other substances in the body). In Alzheimer's disease a protein called amyloid gathers in the brain and is thought to cause symptoms like memory loss and confusion. It is hoped that AAB-001 will attach to the amyloid protein in your brain and help your body to remove it.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of probable AD
* Age from 50 to 85 years, inclusive
* Rosen Modified Hachinski ischemic score less than or equal to 4
* Magnetic Resonance Imaging (MRI) scan consistent with the diagnosis of AD
* Fluency in English
* Stable doses of medications

Exclusion Criteria:

* Significant neurological disease other than AD
* Major psychiatric disorder
* Significant systemic illness
* History of stroke or seizure
* Weight greater than 120kg (264 lbs.)
* History of autoimmune disease
* Smoking more than 20 cigarettes per day
* Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications
* Prior treatment with experimental immunotherapeutics or vaccines for AD
* Presence of pacemakers or foreign metal objects in the eyes, skin, or body

Primary outcomes:
measure: Safety assessments
Secondary outcomes:
measure: Blood levels of administered study drug
measure: Cognitive and functional assessments
Other outcomes:
Locations:
city: Los Alamitos
country: United States
facility: Pharmacology Research Institute
state: California
city: Northridge
country: United States
facility: Pharmacology Research Institute
state: California
Study officials:
affiliation: Pharmacology Research Institute, Northridge
name: Daniel E. Grosz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04775225: Hip Denervation in Juvenile Idiopathic Arthritis With Hip Arthritis
Official title: Hip Denervation in Juvenile Idiopathic Arthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Juvenile Idiopathic Arthritis
Hip Arthritis
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2021-03-01
Enrollment: 120
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients having juvenile idiopathic arthritis (according to ILAR criteria) with hip arthritis were divided into 3 groups. Group 1 received hip denervation and group 2 controlled and received a subcutaneous injection of saline, and group 3 received intra-articular triamcinolone. Outcome measures included pain, tenderness, range of motion, SOLAR, HARISS score. These outcomes were measured at baseline, 2 weeks, and 16 weeks

Detailed description: The aim of the study is to test the effect of denervation of the active hip in JIA and compare it with a placebo without changing systemic treatment during the study. Outcome measures included pain, range of motion, SOLAR score, and Harris functional score.

Eligibility criteria: Inclusion Criteria:

* patients with JIA with unilateral hip arthritis

Exclusion Criteria:

* hip involvement due to other causes including
* septic arthritis
* other connective tissue diseases
* Avascular necrosis

Primary outcomes:
measure: Change in visual analogue scale
timeFrame: Baseline, 2 weeks and 16 weeks
measure: Change in range of motion
timeFrame: Baseline, 2 weeks and 16 weeks
measure: Change in Harris functional score
timeFrame: Baseline, 2 weeks and 16 weeks
measure: semiquantitative tenderness score
timeFrame: Baseline, 2 weeks and 16 weeks
measure: Change in SOLAR score
timeFrame: Baseline, 2 weeks and 16 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: ahmed Elsaman
Study officials:
References:
Clinical trial NCT04516525: The Impact of CRT on Renal Function
Official title: Assessment of the Impact of Resynchronization Therapy on Renal Function
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Chronic Kidney Diseases
Chronic Heart Failure
Keywords: Chronic cardio-renal syndrome biomarkers
Lead sponsor: University of Rzeszow
Sponsor class: OTHER
First posted: 2020-08-18
Enrollment: 74
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients with heart failure who had met the criteria for CRT implantation according to European Society of Cardiology guidelines for the treatment of heart failure

Brief summary: The study is observational, prospective, including patients undergoing CRT-D / CRT-P implantation in the department of cardiology. In the current project, the researchers assumed that the improvement in cardiac function obtained in patients qualified according to the ESC / PTK guidelines for resynchronization therapy may improve renal function in a prospective 12-month follow-up. In addition, it is planned to take into account the possibility of temporary deterioration of kidney function, which may occur immediately after implantation of the resynchronization device due to the nephrotoxic effect of the contrast agent.


Eligibility criteria: Inclusion Criteria:

Adult patients with heart failure who had met the criteria for CRT implantation according to European Society of Cardiology guidelines for the treatment of heart failure

Exclusion Criteria:

* no written consent to participate in the study
* no indications for CR implantation
* current infection
* children
* pregnant women

Primary outcomes:
measure: Evaluation of changes renal function: 48 hours, one month and one year after cardiac resynchronization therapy device implantation procedure.
timeFrame: 1 year for each patient in the study
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Gala-Bladzinska A, Romanek J, Mazur D, Stepek T, Braun M, Szafarz P, Chlebus M, Przybylski A. Reduced Albuminuria and Potassemia Indicate Early Renal Repair Processes after Resynchronization Therapy in Cardiorenal Syndrome Type 2. Cardiol Res Pract. 2020 Mar 21;2020:2727108. doi: 10.1155/2020/2727108. eCollection 2020.
Clinical trial NCT00867022: Autonomic Nervous Activity in Women With Gestational Diabetes
Official title: Autonomic Nervous Activity in Women With Gestational Diabetes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gestational Diabetes
Keywords: Inflammatory factors
Coagulation factors
Sympathetic activity
Lead sponsor: University of Helsinki
Sponsor class: OTHER
First posted: 2009-03-23
Enrollment: 80
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Gestational diabetic women having or not hypertension with two control groups, one pregnant on non-pregnant. All the women are studied during night time to study the arousal of the sympathetic activity in the early morning hours

Brief summary: Through complex hormonal pathways, insulin resistance can lead to the activation of the sympathetic nervous system, and vice versa. Schobel et al. showed that in PE patients, mus-cle sympathetic nerve activity (MSNA) is increased compared with normotensive pregnant and non-pregnant women. Studies assessing heart-rate variability and plasma noradrenalin concentrations also suggest increased sympathetic activity in PE. It has been hypothesized that sympathetic over-activity is a precursor of PE, normally compensated for by vasodilating mechanisms, but resulting in PE when the mechanisms fail. In addition to sympathetic activity, various markers of inflamma-tion are also associated with reduced insulin sensitivity, suggesting that chronic sub-clinical inflamma-tion could be part of the insulin resistance syndrome. The role of sympathetic over-activity and inflammatory markers in gestational diabetes has not been investigated


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of gestational diabetes (OGTT) with or without BP \> 140/90.
* Pregnant control with normal OGTT-

Exclusion Criteria:

* Smoking
* Uncontrolled hypertension
* Diabetes
* Medication affecting sympathetic activity

Primary outcomes:
measure: Serum Noradrenalin level
Secondary outcomes:
measure: Heart rate variability: LF, VLF, HF
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Department of Obstet and Gyn, Helsinki University Hospital
state: Uusimaa
Study officials:
References:
Clinical trial NCT01202422: An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of Two Controlled Release Pregabalin Tablets As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule
Official title: An Open-Label, Multiple-Dose, Randomized, 3-Way Crossover Study In Healthy Volunteers To Determine The Steady-State Pharmacokinetics Of The 165 Mg And 330 Mg Dose Strengths Of Pregabalin Controlled Release Formulations Administered Following An Evening Meal And 150 Mg Of The Immediate Release Formulation Administered Twice Daily
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: pregabalin
pharmacokinetics
bioavailability
bioequivalence
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2010-09-15
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The purpose of this study is to 1) evaluate the extent of absorption of multiple doses of two pregabalin controlled release tablets as compared to multiple doses of the pregabalin immediate release capsule, 2) evaluate the pharmacokinetics of multiple doses of two pregabalin controlled release tablets as compared to multiple doses of pregabalin immediate release capsule and 3) evaluate the safety and tolerability of multiple doses of two pregabalin controlled release tablets as compared to multiple doses of the pregabalin immediate release capsule.

Detailed description: Evaluate the absorption, pharmacokinetics, safety/tolerability of multiple doses of two pregabalin controlled release tablets as compared to multiple doses of pregabalin immediate release capsule

Eligibility criteria: Inclusion Criteria:

* Healthy male or females
* Between the ages of 18 and 55 years, inclusive
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2

Exclusion Criteria:

* Illicit drug use
* Pregnant or nursing females
* Females of childbearing potential who are unwilling or unable to use an acceptable method of contraception

Primary outcomes:
measure: Area under the curve at steady-state over a 24 hour period (AUC24)for assessment of equivalence between 330 mg CR and 150 mg IR (total daily dose 300 mg)
timeFrame: 5 days
measure: AUC24 and maximum plasma concentration over a 24 hour period (Cmax) at steady-state for assessment of equivalence between the 165 mg CR (two tablets administered concurrently) and 330 mg CR
timeFrame: 5 days
Secondary outcomes:
measure: Safety endpoints include evaluation of adverse events.
timeFrame: 5 days
Other outcomes:
Locations:
city: Bruxelles
country: Belgium
facility: Pfizer Investigational Site
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
citation: Chew ML, Alvey CW, Plotka A, Pitman VW, Alebic-Kolbah T, Scavone JM, Bockbrader HN. Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies. Clin Drug Investig. 2014 Sep;34(9):627-37. doi: 10.1007/s40261-014-0221-2.
Clinical trial NCT01154322: Pediatric Nasal Mask Usability Study
Official title: Pediatric Nasal Mask Usability Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obstructive Sleep Apnea
Lead sponsor: ResMed
Sponsor class: INDUSTRY
First posted: 2010-06-30
Enrollment: 16
Sex: ALL
Minimum age (years): 2
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to demonstrate the effectiveness of a pediatric mask in treating obstructive sleep apnea (OSA) in a pediatric population.

Detailed description: Obstructive sleep apnea (OSA) is a condition in which there is partial or complete collapse of the upper airway during sleep. Features of OSA include snoring to upper airway resistance, which could be mild to severe. While OSA has been studied extensively in an adult population, research indicates that OSA is prevalent in a pediatric population as well, though the options for treatment are not as varied as that for the adult population. The study seeks to determine if a mask made for a pediatric population effectively treats their OSA.

Eligibility criteria: Inclusion Criteria:

* 2-7 years of age
* Diagnosis of OSA
* Current PAP therapy user
* Current nasal mask user

Exclusion Criteria:

* Recent sinus surgery
* Allergies to mask material
* Current seasonal allergies that could interfere with therapy
* History of clinically significant epistaxis in past 6 months
* Upper airway surgery less than 60 days before study entry

Primary outcomes:
measure: Apnea-hypopnea Index (AHI) Using the New Pediatric Mask (Pixi) Compared to the Child's Currently-used Mask
timeFrame: Baseline AHI
measure: Apnea-Hypopnea Index (AHI) Using the New Pediatric Mask (Pixi) Compared to the Child's Currently-used Mask
timeFrame: AHI after min 21 days use with Pixi mask
Secondary outcomes:
Other outcomes:
Locations:
city: Redwood City
country: United States
facility: Stanford Center for Human Sleep Research
state: California
city: Aurora
country: United States
facility: The Children's Hopsital
state: Colorado
city: Wallingford
country: United States
facility: Gaylord Sleep Medicine
state: Connecticut
Study officials:
References:
Clinical trial NCT01969422: Online Question-answering and Conventional Consultation With a Dermatologist
Official title: Online Question-answering and Conventional Consultation With a Dermatologist
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Skin Diseases
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2013-10-25
Enrollment: 100
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: persons with a question on skin disease

Brief summary: Comparison of online question-answering system and conventional consultation for dermatological questions:

* same diagnosis?
* same information, which had been collected?
* same recommendations about treatment?
* what were the relevant differences of the two?

Detailed description: mainly, ICD codes and dermatological diagnosis codes according to the AAD will be used.

Eligibility criteria: Inclusion criteria:

- a conventional dermatological consultation after a question in the online question-answering system.

Exclusion criteria:

-power of veto after information of patient

Primary outcomes:
measure: Correlation of online and clinical diagnosis by Spearman's Rho
timeFrame: physical consultation date
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Department of Dermatology
state: ZH
Study officials:
affiliation: University Hospital Zurich, Department of Dermatology
name: Guenther Hofbauer, Prof MD
role: PRINCIPAL_INVESTIGATOR
References: